Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
By D. Haller, J. Tabernero, J. Maroun, F. D. De Braud, T. Price, E. Van Cutsem, M. Hill, F. Gilberg, K. Rittweger, H. Schmoll. Journal of Clinical Oncology, 2011
728 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/dad3828370188e523418244a2483dc647ae3fcdc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, result): “All showed significant improvement in DFS compared with fluoropyrimidine as single agent [69-71].”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “On the other hand, in an integrated analysis of three randomized controlled trials in Europe and the United States targeting Dukes’ B and Dukes’ C, 5‑FU + l‑LV was associated with significantly better relapse‑free survival and overall survival in comparison to surgery alone [301].”
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, methodology): “The XELOXA international phase III study [32] assessed the safety and efficacy of adjuvant capecitabine plus oxaliplatin (XELOX) versus bolus FU/LV (Mayo Clinic or Roswell Park regimen) in stage III patients: the arm including the oral compound was well tolerated and superior to the i.”